Adaptive Biotechnologies Corporation (NASDAQ: ADPT) — FY 2020 Form 10-K
Reporting period: Fiscal year ended December 31, 2020. This is an annual filing, not a standalone fourth-quarter report. The company develops immune-sequencing research tools and diagnostics, including clonoSEQ and T-Detect, and collaborates on therapeutic discovery.
Financial performance and liquidity
| Metric | FY 2020 | FY 2019 | Change |
|---|---|---|---|
| Total revenue | $98.4 million | $85.1 million | Up 16% |
| Sequencing revenue | $41.4 million | $43.5 million | Down 5% |
| Development revenue | $56.9 million | $41.6 million | Up 37% |
| Operating expenses | $251.2 million | $163.5 million | Up 54% |
| Operating loss | $(152.8) million | $(78.4) million | Loss widened |
| Net loss | $(146.2) million | $(68.6) million | Loss widened |
| Net loss per share | $(1.11) | $(1.01) | |
| Cash used in operating activities | $(149.7) million | Cash provided: $205.4 million | Shifted to cash use |
- Gross profit was approximately $75.9 million, or a 77% gross margin, based on reported revenue less cost of revenue. Operating margin was approximately negative 155%.
- Cash, cash equivalents and marketable securities totaled $806.8 million at year-end, versus $682.3 million a year earlier. Current assets were $726.9 million and current liabilities $105.2 million.
- No conventional borrowings are reported in the balance sheet. Operating lease liabilities were $107.9 million; undiscounted lease payments totaled $149.6 million. The company reported $2.1 million of restricted cash associated with a letter of credit.
- A July 2020 equity offering raised approximately $271.8 million net. Year-end shareholders’ equity was $743.3 million; accumulated deficit was $511.6 million.
Material changes and business developments
- Revenue growth was driven by development revenue, including $52.8 million recognized under the Genentech collaboration. Genentech-related revenue represented 53.7% of total revenue in the MD&A; the filing’s customer concentration note separately reports 55.8% for Genentech and the Roche Group.
- Research sequencing volume fell 36% to 22,663 sequences, reflecting a prior agreement’s expiration and customer trial delays and deferrals, including pandemic-related disruption. Clinical test volume rose 50% to 15,216, including clonoSEQ and T-Detect.
- clonoSEQ tests delivered increased 49% to 15,186. Its FDA label expanded to CLL samples from blood and bone marrow; a filing to expand ALL use to blood was submitted in February 2021.
- 2020 spending rose substantially: research and development increased 64% to $116.1 million; sales and marketing increased 60% to $61.4 million; and general and administrative expenses increased 63% to $49.5 million. Management attributed spending growth to platform and product development, commercialization, staffing and public-company costs.
- The company reported $786.8 million in cash and marketable securities on the balance sheet, while its stated combined liquidity figure of $806.8 million also includes cash equivalents. It said it expected existing liquidity to fund operations and capital needs for at least 12 months.
Outlook, risks and notable items
- No quantified revenue, earnings or cash-flow guidance is provided. Management expects continued investment and operating losses, and anticipates higher near-term capital spending for laboratory and office expansion.
- Management targeted a T-Detect Lyme CLIA-service launch toward the end of 2021, subject to study and validation progress. Genentech planned to submit an IND for the first shared cellular therapy in the first half of 2021. These are forward-looking plans, not reported outcomes.
- The company applied for EUA for T-Detect COVID; the filing states the test was offered as an LDT and that EUA status could affect liability protections and reimbursement. The filing’s performance claims are based on company-described studies and should not be treated as a guarantee of clinical utility or commercial adoption.
- Key risks include continued losses and cash use; dependence on Genentech and milestone-based revenue; uncertainty in clinical validation, regulatory clearance and reimbursement; customer and trial disruption from COVID-19; competition; and reliance on limited or single suppliers, particularly Illumina for sequencing equipment and reagents.
- Genentech milestone payments and royalties are contingent, not assured. The company estimated up to approximately $1.8 billion in additional collaboration milestones, plus potential royalties; it also disclosed up to $313.5 million in potential milestones under MRD development agreements.
- Management reported effective disclosure controls and internal control over financial reporting at year-end. The auditor issued unqualified opinions on the financial statements and internal controls. The auditor identified estimation of total expected Genentech collaboration costs as a critical audit matter, reflecting judgment in revenue recognition.
Investor verification priorities
- Reconcile the reported Genentech revenue concentration: 53.7% in MD&A versus 55.8% for Genentech and Roche Group in the customer concentration note.
- Track operating cash burn and the recognition of deferred Genentech revenue, including the assumptions behind estimated collaboration costs and development timelines.
- Verify subsequent progress on T-Detect COVID EUA, Lyme validation and launch plans, clonoSEQ label expansions, and the planned Genentech IND submission.
- Assess whether clinical test growth, reimbursement and customer adoption can offset declining research sequencing revenue and the sharply higher operating expense base.
- Review lease commitments and planned facility spending alongside liquidity; also distinguish cash and cash equivalents from total cash, cash equivalents and marketable securities.